Amarin Corporation plc (AMRN) |
|
1.44 -0.05 (-3.36%)
|
07-02 19:48 |
|
Open: |
1.46 |
Pre. Close: |
1.49 |
|
High:
|
1.49 |
Low:
|
1.2 |
|
Volume:
|
10,869,076 |
Market Cap:
|
572(M) |
|
|
|
|
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.49 - 1.5 |
1.5 - 1.51 |
|
Low:
|
1.18 - 1.19 |
1.19 - 1.2 |
|
Close:
|
1.42 - 1.44 |
1.44 - 1.45 |
|
Technical analysis |
as of: 2022-07-01 4:20:01 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time. |
| Target: |
Six months: 2  One year: 2.37 |
| Support: |
Support1: 1.2 Support2: 0.99 |
| Resistance: |
Resistance1: 1.71 Resistance2: 2.02 |
| Pivot: |
1.78 |
| Moving Average: |
MA(5): 1.7 MA(20): 1.78
MA(100): 2.5 MA(250): 3.6 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 28.9 %D(3): 43.1 |
| RSI: |
RSI(14): 34.9 |
| 52-week: |
High: 5.96 Low: 1.11 |
| Average Vol(K): |
3-Month: 4,911 (K) 10-Days: 4,207 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AMRN ] has closed below the lower bollinger band by 9.1%. Bollinger Bands are 31.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Sat, 02 Jul 2022
Amarin (NASDAQ:AMRN) Rating Lowered to Sell at StockNews.com - Defense World
Fri, 01 Jul 2022
Why Amarin Stock Is Sinking Today - The Motley Fool
Fri, 24 Jun 2022
Do Analysts Expect Amarin Corporation plc (AMRN) Stock to Rise After It Has Risen 43.38% in a Month? - InvestorsObserver
Wed, 15 Jun 2022
Sarissa Capital Intends to Vote “Abstain” at the Amarin Annual Meeting - Business Wire
Tue, 14 Jun 2022
Amarin Beats Investor Bid to Revive Heart Disease Drug Dispute - Bloomberg Law
Fri, 10 Jun 2022
How Will the Market React to Amarin Corporation plc (AMRN) Stock Getting a Neutral Rating - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
396 (M) |
| Shares Float |
345 (M) |
|
% Held by Insiders
|
1.2 (%) |
|
% Held by Institutions
|
36.1 (%) |
|
Shares Short
|
18,090 (K) |
|
Shares Short P.Month
|
16,490 (K) |
Stock Financials |
|
EPS
|
-0.02 |
|
EPS Est Next Qtl
|
-0.03 |
|
EPS Est This Year
|
-0.21 |
|
EPS Est Next Year
|
-0.06 |
|
Book Value (p.s.)
|
1.62 |
|
Profit Margin (%)
|
1.3 |
|
Operating Margin (%)
|
4.1 |
|
Return on Assets (ttm)
|
1.4 |
|
Return on Equity (ttm)
|
1.1 |
|
Qtrly Rev. Growth
|
-13.7 |
|
Gross Profit (p.s.)
|
1.16 |
|
Sales Per Share
|
1.47 |
|
EBITDA (p.s.)
|
0.06 |
|
Qtrly Earnings Growth
|
305.8 |
|
Operating Cash Flow
|
-67 (M) |
|
Levered Free Cash Flow
|
70 (M) |
Stock Valuations |
|
PE Ratio
|
-130.91 |
|
PEG Ratio
|
-0.2 |
|
Price to Book value
|
0.88 |
|
Price to Sales
|
0.97 |
|
Price to Cash Flow
|
-8.57 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
